<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01146444</url>
  </required_header>
  <id_info>
    <org_study_id>DL0814-SPRG0801/KHMR</org_study_id>
    <nct_id>NCT01146444</nct_id>
  </id_info>
  <brief_title>Sunscreens in Patients With Cutaneous Lupus Erythematosus(CLE)</brief_title>
  <official_title>Investigation of the Efficacy of Different Sunscreens in Patients With Photosensitive Cutaneous Lupus Erythematosus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spirig Pharma Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spirig Pharma Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Part I: to investigate the efficacy of different sunscreens in the prevention of skin lesions&#xD;
      following standardized photoprovocation with Ultraviolet A/Ultraviolet B (UVA/UVB) light in&#xD;
      patients with CLE.&#xD;
&#xD;
      Part II: to evaluate the influence of different sunscreens on the expression of biomarkers in&#xD;
      the skin of patients with CLE and of Healthy Controls following UV irradiation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part I&#xD;
&#xD;
      Part I-interventions will be:&#xD;
&#xD;
        -  Experimental intervention: Application of broad-spectrum sunscreens with a low, medium,&#xD;
           and high Sun Protection Factor (SPF) in random order to uninvolved skin areas prior to&#xD;
           standardized photoprovocation.&#xD;
&#xD;
        -  Control intervention: Intra-individual application of vehicle in random order;&#xD;
           standardized photoprovocation of vehicle treated and untreated areas.&#xD;
&#xD;
      Part II&#xD;
&#xD;
      Part II-interventions will be:&#xD;
&#xD;
        -  Experimental intervention: Application of a broad-spectrum sunscreen with a high SPF to&#xD;
           uninvolved skin areas prior to UV irradiation.&#xD;
&#xD;
        -  Control intervention: UV irradiation of untreated areas.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prevention of skin lesions following standardized photoprovokation with UVA/UVB light in patients with CLE</measure>
    <time_frame>September 2011</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Cutaneous Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>sunscreens with a low, medium, high SPF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>sunscreens with a low, medium, and high SPF. UVA and UVB irradiation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>vehicle</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intra-individual application of vehicle in random order; UVA and UVB irradiation</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>UV A and B irradiation</intervention_name>
    <description>UV irradiation</description>
    <arm_group_label>sunscreens with a low, medium, high SPF</arm_group_label>
    <arm_group_label>vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with subacute cutaneous lupus erythematosus (SCLE), discoid lupus&#xD;
             erythematosus (DLE), or lupus erythematosus tumidus (LET) according to the Düsseldorf&#xD;
             Classification 2004 (Kuhn and Ruzicka 2004) confirmed by histological analysis.&#xD;
&#xD;
          -  Women of childbearing potential with a negative pregnancy test at screening (urine&#xD;
             test) and using a medically accepted contraceptive regimen (intra-uterine device,&#xD;
             partner's vasectomy, &gt;3 months previous hormonal contraception (oestrogen plus&#xD;
             gestagen pill, depot injections, or subcutaneous depot) combined with a barrier method&#xD;
             (preservative, vaginal diaphragm, cervical cap, spermicide) during the study and for 8&#xD;
             weeks after the last UV exposure.&#xD;
&#xD;
          -  Women clinically sterile (post-menopausal, undergone hysterectomy or tubal ligation).&#xD;
&#xD;
          -  Actively cooperating to participate in the study, to follow the instructions of the&#xD;
             investigator and to attend the centre at the agreed times.&#xD;
&#xD;
          -  Development of skin lesions any time under current systemic treatment if patient is&#xD;
             receiving systemic medication for the treatment of CLE.&#xD;
&#xD;
          -  Signed informed consent form after the nature of the study has been fully explained.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy or lactation and women with positive pregnancy test.&#xD;
&#xD;
          -  Known hypersensitivity or allergic contact reactions to components of the study&#xD;
             agents.&#xD;
&#xD;
          -  Treatment with photosensitizing drugs.&#xD;
&#xD;
          -  Exposure to direct natural (sunlight) or artificial UV radiation on the back within 4&#xD;
             weeks prior to entering the study.&#xD;
&#xD;
          -  History of another photodermatosis, except polymorph light eruption (PLE).&#xD;
&#xD;
          -  Any current known skin malignancy or any history of skin malignancy within the&#xD;
             previous 5 years or Xeroderma pigmentosum.&#xD;
&#xD;
          -  Initiation or change in the dose of any current systemic medication for the treatment&#xD;
             of CLE within 8 weeks prior to standardized photoprovocation.&#xD;
&#xD;
          -  Local therapy for the treatment of CLE within two weeks prior to standardized&#xD;
             photoprovocation at the back of the patient&#xD;
&#xD;
          -  Acute exacerbation of CLE skin disease within 2 weeks prior to entering the study.&#xD;
&#xD;
          -  Acute illness within 7 days prior to phototesting or major illness including infection&#xD;
             or hospitalization within 1 month of study entry.&#xD;
&#xD;
          -  Anti-dsDNA (RIA) &gt; 7 U/ml and/or at least one of the following criteria:&#xD;
&#xD;
          -  Serositis: pleuritis or pericarditis documented by electrocardiogram or rub or&#xD;
             evidence of pericardial effusion;&#xD;
&#xD;
          -  Renal disorder: proteinuria greater than 0.5 g/d or greater than 3+, or cellular&#xD;
             casts;&#xD;
&#xD;
          -  Neurologic disorder: seizures or psychosis without other cause.&#xD;
&#xD;
          -  Patients with a documented HIV and/or hepatitis B or C infection.&#xD;
&#xD;
          -  Any medical condition, which would place the subject at undue risk of, or make it&#xD;
             unlikely that follow-up-measurements could be obtained&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Annegret Kuhn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinik und Poliklinik für Hautkrankheiten, Universitätsklinikum Münster</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <study_first_submitted>May 24, 2010</study_first_submitted>
  <study_first_submitted_qc>June 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2010</study_first_posted>
  <last_update_submitted>March 8, 2016</last_update_submitted>
  <last_update_submitted_qc>March 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sunscreening Agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
    <mesh_term>Lupus Erythematosus, Cutaneous</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

